Compare Crowdstrike Holdings Inc (CRWD) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs McKesson Corporation — how do they compare? Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: Crowdstrike Holdings Inc is far larger — about 2.5× McKesson Corporation's market cap, and McKesson Corporation pays a 0.4% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and McKesson Corporation for 74 Days on average.
| CRWD | MCK | |
|---|---|---|
Market Cap | $269.31B | $108.46B |
Volume | 9,381,560 | 712,607 |
Sector | Technology | Health |
52-Week High | $278.86 | $995.69 |
52-Week Low | $87.56 | $725.17 |
Typical Hold Time | 97 Days | 74 Days |
Enterprise Value | $265.11B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $263.01, down 0.92% today but near its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Revenue growth remains robust at $3.95B for 2025, though profitability is challenged with a net margin of -0.49%. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $239.38 consensus target, while recent news highlights AI-driven cybersecurity demand as a key growth catalyst.
Outlook remains favorable given CrowdStrike's leadership in AI-native cybersecurity and expanding market opportunities. However, elevated valuation multiples (P/S 49.86) and competitive pressures present risks. The stock's proximity to all-time highs suggests near-term consolidation potential, but long-term growth prospects in cybersecurity remain compelling.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
